Chapel Hill, NC, United States of America

Philip Floyd Hughes

This inventor holds 27 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Pharmaceutical Compounds. Top assignees: Duke University, American Home Products Corporation, Eli Lilly and Company. Active years: 1988-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip Floyd Hughes. Retrieved from https://idiyas.com/inventor/philip-floyd-hughes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 

% Patents Active = 85.2

 

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 576(Granted Patents)


Location History:

  • Lake Hopatcong, NJ (US) (1992)
  • Hopewell, NJ (US) (1988 - 1993)
  • Chapel Hill, NC (US) (1992 - 2023)

Company Filing History:


Years Active: 1988-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Disease Treatment
Cancer Therapy
HSP90 Inhibitors
Fatty Acid Synthase
Benzimidazoles
Immunosuppressive Agents
Potassium Channel Inhibitors
Pharmaceutical Compositions
Heat Shock Proteins
Indazolyl Derivatives
2-Oxocyclohexaneacetic Acid
Rapamycin Analogs
27 patents (USPTO):Explore Patents

Title: Philip Floyd Hughes: Trailblazer in Cancer Treatment Innovations

Introduction

Philip Floyd Hughes is an accomplished inventor based in Chapel Hill, NC, with an impressive portfolio of 25 patents. His expertise in biotechnology and pharmaceutical developments has led to significant advancements in cancer treatment, focusing on innovations that target key biological pathways.

Latest Patents

Hughes' latest patents include groundbreaking work on "Compositions and methods for the treatment of cancer." This disclosure presents compounds and pharmaceutical compositions aimed at inhibiting Heat Shock Transcription Factor 1 (HSF1) activity. The research details methods for treating diseases associated with HSF1 function, particularly cancer. Another notable patent is related to "Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase." This patent introduces inhibitors of TAK1, providing methods to utilize these compounds for the treatment of various diseases.

Career Highlights

Throughout his career, Hughes has made significant contributions to the fields of biotechnology and pharmaceutical sciences. He has held positions at renowned institutions such as Duke University, where he engaged in groundbreaking research, and American Home Products Corporation, where he further honed his expertise in drug development and innovation.

Collaborations

In his journey, Hughes has collaborated with distinguished colleagues, including Timothy Haystead and Timothy A. J. Haystead. These associations have allowed for a rich exchange of ideas and research, propelling advancements in the medical field and leading to patentable inventions.

Conclusion

Philip Floyd Hughes exemplifies the spirit of innovation in the realm of cancer treatment. His extensive patent portfolio and dedication to research highlight the importance of interdisciplinary collaborations and cutting-edge scientific inquiry in improving health outcomes. As he continues to explore new frontiers in biotechnology, his work remains a vital contribution to the ongoing fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…